Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone908-200-7500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.54 million
Profitability
Miscellaneous
Employees133
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions
What is Celldex Therapeutics' stock symbol?
Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."
When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?
Celldex Therapeutics's stock reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.
How were Celldex Therapeutics' earnings last quarter?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.20) by $0.25. The biopharmaceutical company had revenue of $1.76 million for the quarter, compared to analysts' expectations of $1.46 million. Celldex Therapeutics had a negative net margin of 1,585.40% and a negative return on equity of 53.51%. View Celldex Therapeutics' Earnings History.
When is Celldex Therapeutics' next earnings date?
What price target have analysts set for CLDX?
5 analysts have issued 12-month price objectives for Celldex Therapeutics' shares. Their forecasts range from $30.00 to $45.00. On average, they anticipate Celldex Therapeutics' share price to reach $37.50 in the next twelve months. This suggests a possible upside of 659.1% from the stock's current price. View Analyst Price Targets for Celldex Therapeutics.
What is the consensus analysts' recommendation for Celldex Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celldex Therapeutics.
What are Wall Street analysts saying about Celldex Therapeutics stock?
Here are some recent quotes from research analysts about Celldex Therapeutics stock:
- 1. According to Zacks Investment Research, "Following the discontinuation of glembatumumab vedotin studies, Celldex is focused on developing its anti-cancer pipeline candidates including CDX-301, which is being developed for the lucrative lung cancer market. Celldex also has collaborations with big pharma companies, which lend solid support as well as expertise. Meanwhile, the Kolltan acquisition added some interesting candidates to the company’s pipeline. However, the failure of glembatumumab vedotin was a major setback. With no approved products, further pipeline setbacks will severely impact Celldex. The company depends entirely on product development, licensing agreements, contracts and grants for revenues. Shares of the company have significantly underperformed the industry in the past year. Estimates movement has been mixed ahead of Q4 earnings. Celldex has a positive record of earnings surprises in the recent quarters." (2/19/2019)
- 2. Cowen Inc analysts commented, "We are pleased with Endo’s beat and raise quarter as the company continues to pivot itself into a more specialized company with foci on durable brands like Xiaflex, specialty injectables and a specialty generic base business. As such, the strength in the shares seen post earnings likely indicates that investors are pleased with management’s recent actions (as are we). At the same time we continue to view current debt levels, ongoing opioid litigation, and legal liabilities as significant overhangs on the name that could stunt momentum and remain HOLD rated on ENDP shares." (8/9/2018)
Has Celldex Therapeutics been receiving favorable news coverage?
News articles about CLDX stock have trended somewhat negative recently, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Celldex Therapeutics earned a news impact score of -1.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Celldex Therapeutics' key competitors?
Some companies that are related to Celldex Therapeutics include Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), Trinity Biotech (TRIB), Riot Blockchain (RIOT), ImmuCell (ICCC), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Akers Biosciences (AKER), Arca Biopharma (ABIO), Fluoropharma Medical (FPMI), BG Medicine (BGMD) and Response Genetics (RGDXQ).
What other stocks do shareholders of Celldex Therapeutics own?
Who are Celldex Therapeutics' key executives?
Celldex Therapeutics' management team includes the folowing people:
- Mr. Anthony S. Marucci, Founder, Pres, CEO & Director (Age 57)
- Dr. Tibor Keler, Founder, Chief Scientific Officer & Exec. VP (Age 60)
- Mr. Sam Martin, Sr. VP, CFO, Sec. & Treasurer (Age 48)
- Ms. Elizabeth Crowley, Chief Product Devel. Officer & Sr. VP (Age 47)
- Dr. Richard M. Wright Ph.D., Chief Commercial Officer & Sr. VP (Age 55)
Who are Celldex Therapeutics' major shareholders?
Celldex Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (31.06%), Dimensional Fund Advisors LP (31.06%), BlackRock Inc. (1.08%), Two Sigma Investments LP (15.14%), Acadian Asset Management LLC (0.80%) and Geode Capital Management LLC (9.74%). Company insiders that own Celldex Therapeutics stock include James J Marino and Tibor Keler. View Institutional Ownership Trends for Celldex Therapeutics.
Which institutional investors are selling Celldex Therapeutics stock?
CLDX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, GSA Capital Partners LLP, TSP Capital Management Group LLC, Northern Trust Corp, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP and Two Sigma Advisers LP. View Insider Buying and Selling for Celldex Therapeutics.
Which institutional investors are buying Celldex Therapeutics stock?
CLDX stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Stratos Wealth Partners LTD., Telemetry Investments L.L.C., Geode Capital Management LLC, Geode Capital Management LLC and Two Sigma Investments LP. Company insiders that have bought Celldex Therapeutics stock in the last two years include James J Marino and Tibor Keler. View Insider Buying and Selling for Celldex Therapeutics.
How do I buy shares of Celldex Therapeutics?
Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celldex Therapeutics' stock price today?
One share of CLDX stock can currently be purchased for approximately $4.94.
How big of a company is Celldex Therapeutics?
Celldex Therapeutics has a market capitalization of $61.45 million and generates $9.54 million in revenue each year. The biopharmaceutical company earns $-151,180,000.00 in net income (profit) each year or ($6.82) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.
What is Celldex Therapeutics' official website?
How can I contact Celldex Therapeutics?
Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]
MarketBeat Community Rating for Celldex Therapeutics (NASDAQ CLDX)
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe CLDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
